



Profile

Formycon is a globally operating, independent biosimilar specialist with a highly attractive product pipeline and a fully scalable development platform in the fields of ophthalmology, immunology, immuno-oncology and other major indications. With its biosimilars – follow-on products for approved biopharmaceutical drugs – Formycon is making a significant contribution to improving patient access to highly effective and affordable medicines.

Field of activity

Formycon is a "pure-play" biosimilar company. Given its specialized area of focus, the company can cover the entire technical-pharmaceutical development chain, from drug candidate selection, cell line development, comparative analytics, process development and preclinical and clinical development. The team also


has extensive expertise in the preparation of approval documents and management of approval procedures in highly regulated markets as well as in establishing and managing all supply chain and product logistics.

Products/Services

In addition to FYB201 (reference product Lucentis®), which has already been approved and launched in key global markets (US, EU, UK, Canada, MENA, etc.), Formycon's development pipeline includes two additional biosimilars as well as four biosimilar candidates with attractive market potential.

The biosimilar FYB202 (reference product Stelara®) was recently approved in the US and in the EU. FYB203 (reference product Eylea®) was approved in the US and is at an advanced stage of the approval process in the EU.

Development pipeline



The biosimilar candidate FYB206 for the immuno-oncology blockbuster drug Keytruda® is currently undergoing clinical evaluation in parallel Phase I and Phase III trials.

The two undisclosed biosimilar candidates FYB208 and FYB209 are in advanced pre-clinical development. In addition, the new biosimilar development project FYB210 was started in November 2024.

Partnering

Formycon relies on strong, trustworthy and long-term partnerships around the world for the commercialization of its biosimilars. Formycon has a 50% share in the biosimilar FYB201, which is marketed by Sandoz AG in the US, Teva Pharmaceutical Industries Ltd. in the EU and other territories, and MS Pharma in the MENA region. A global commercialization partnership has been concluded with Fresenius Kabi for FYB202, and negotiations on commercialization partnerships for FYB203 in the US and Europe are at an advanced stage. The project and commercialization rights for FYB206, FYB208, FYB209 and FYB210 are held in full by Formycon.

Contact

Sabrina Müller
 Director Investor Relations and
 Corporate Communications
 ir@formycon.com

www.formycon.com



About Formycon

Founded: 2012
 Sitz: Planegg near Munich
 Employees: > 240

Management Board

Dr. Stefan Glombitza (CEO)
 Nicola Mikulcic (CBO)
 Dr. Andreas Seidl (CSO)
 Enno Spillner (CFO)


Supervisory Board

Wolfgang Essler (Chairman)
 Colin Bond (Deputy Chairman)
 Klaus Röhrig (Member)
 Nicholas Haggart (Member)
 Dr. Bodo Coldewey (Member)

Market data

ISIN: DE000A1EWVY8
 Market Segment: Frankfurt Stock Exchange: Regulated Market (Prime Standard)
 Market Capitalization: ~ € 900 million
 Outstanding Shares: 17,664,427

Shareholder Structure



Key financials (in € million)

	2019	2020*	2021*	2022*	2023*
Revenue	33,2	34,3	36,6	42,5	77,7
EBITDA	-1,4	-5,7	-12,4	-15,9	1,5
Adjusted EBITDA	--	--	--	-28,8	13,3
Net Income	-2,3	-6,7	-13,3	36,0	75,8
Working Capital	22,7	44,4	29,5	14,0	38,9

Formycon News

<https://www.formycon.com/en/news-media/press-releases/>



This document may contain forward-looking statements and information which are based on our current expectations and certain assumptions. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, performance of the company, development of the products and the estimates given here. Such known and unknown risks and uncertainties comprise, among others, the research and development, the regulatory approval process, the timing of the actions of regulatory bodies and other governmental authorities, clinical results, changes in laws and regulations, product quality, patient safety, patent litigation, contractual risks and dependencies from third parties. With respect to pipeline products, Formycon AG does not provide any representation, warranties or any other guarantees that the products will receive the necessary regulatory approvals or that they will prove to be commercially exploitable and/or successful. Formycon AG assumes no obligation to update these forward-looking statements or to correct them in case of developments which differ from those anticipated. This document neither constitutes an offer to sell nor a solicitation of an offer to buy or subscribe for securities of Formycon AG. No public offering of securities of Formycon AG will be made nor is a public offering intended. This document and the information contained therein may not be distributed in or into the United States of America, Canada, Australia, Japan or any other jurisdictions, in which such offer or such solicitation would be prohibited. This document does not constitute an offer for the sale of securities in the United States.

Keytruda® is a registered trademark of Merck Sharp & Dohme U.S., Stelara® is a registered trademark of Johnson & Johnson, Eylea® is a registered trademark of Regeneron Pharmaceuticals, Inc., Lucentis® is a registered trademark of Genentech, Inc. and further territories

*According to IFRS

2024/11